It is the first Monday of the quarter, and a medical-affairs insights lead is staring at a shared drive that holds the raw field output of fourteen Medical Science Liaisons across two therapeutic areas: roughly two hundred and ten interaction records from the last ninety days, captured in Veeva CRM, in OneNote, in email, and in a few cases as voice memos transcribed by whatever the MSL had on their phone. Buried in that pile is the signal the brand team and the medical strategy lead actually need before the advisory board in three weeks: what the key opinion leaders are really saying about the dosing schedule, where the unmet-need narrative is shifting, and which competitor data is reshaping the conversation. The temptation is to paste the whole pile into the enterprise model and ask for a strategic insights report. That single action, taken in the wrong order, is how a medical-affairs function ends up with named investigators, advisory-board members, and patient-identifying detail flowing through a synthesis step that was never designed to protect them. This lesson designs the end-to-end workflow that gets from raw multi-MSL intake to an MLR-cleared strategic report, and it treats de-identification not as a courtesy but as a non-negotiable precondition that gates every downstream step.

Why Field Insight Is a Workflow, Not a Summarization Task

The instinct of most teams is to treat field-insight synthesis as a summarization problem: take the notes, compress them, surface the themes. That framing is wrong in a way that matters, because the value of a medical insight does not live in any single note; it lives in the pattern across notes, and the pattern is invisible until the records have been normalized, de-identified, clustered, and weighted against strategy. A senior endocrinology KOL telling one MSL that the titration schedule is impractical in elderly patients is an anecdote. The same concern surfacing independently across nine MSLs and six institutions is a strategic signal that belongs in the advisory-board agenda and possibly in the next protocol amendment. The workflow exists to convert a heap of anecdotes into a defensible signal, and every stage of it has a distinct failure mode that a one-shot summarization prompt cannot see, let alone guard against.

There is also a regulatory reason the summarization framing is dangerous. Medical-affairs field insight sits inside the scientific-exchange function, which is firewalled from commercial promotion, and the moment a synthesized insight is used to shape a brand message it has crossed into territory governed by promotional rules, off-label restrictions, and the sunshine-act transparency regime. A workflow that cannot show where a strategic claim came from, which MSL captured it, whether it was on-label, and how it was de-identified before processing is a workflow that cannot survive a compliance review. The design discipline of this lesson is to make every one of those questions answerable by construction, so that the strategic report the brand team receives is both more useful and more defensible than anything a single analyst could assemble by hand.

Stage One: Multi-MSL Intake and Normalization

The first stage takes fourteen MSLs' worth of heterogeneous records and renders them into a single normalized structure before any model touches the content for synthesis. Normalization here means mapping every record, regardless of source system, onto a common schema: interaction date, therapeutic area, the topic taxonomy the medical-strategy team uses, the type of engagement (one-to-one, advisory contribution, congress conversation), the on-label or off-label flag, and a free-text insight field. This is itself an AI-assisted step, because the raw records are inconsistent in exactly the ways human-authored field notes always are, and a model is genuinely good at proposing a structured mapping from messy prose. But the model's structuring proposal is a draft, not a determination, because a misrouted topic tag at this stage silently distorts every cluster downstream, and an off-label conversation mis-flagged as on-label can travel all the way into a brand deliverable.

The critical design decision in stage one is that intake and de-identification must be sequenced correctly, and the sequencing is counterintuitive. You cannot de-identify reliably until you have normalized enough to know which fields carry identity, and you must not perform open-ended synthesis until you have de-identified. The workflow therefore runs normalization on a controlled, access-restricted model deployment, one inside the sponsor's validated environment with a business-associate agreement and zero-data-retention configuration, precisely because the raw records at this stage still contain the names of KOLs, their institutions, the patient details they discussed, and in some cases competitor advisory-board affiliations that are themselves confidential. The naive shortcut of normalizing in a public tool to save time is the single most common way real medical-affairs teams leak the most sensitive relationships they own.

Stage Two: De-Identification as the Non-Negotiable Gate

De-identification is the hinge of the entire workflow, and it is the step that most teams treat as optional and most regulators treat as foundational. The reason it is non-negotiable is specific to the medical-affairs context: the KOLs an MSL engages are not anonymous members of the public. They are named investigators on the sponsor's own pivotal trials, members of advisory boards bound by confidentiality agreements, authors with disclosed competing interests, and sometimes clinicians at a single identifiable institution where the patient described in a clinical anecdote could be re-identified from the combination of condition, timing, and site. A synthesis step that processes these records with identities intact is not merely a privacy risk; it is a step that can expose a named investigator's private scientific opinion, a competitor's confidential advisory relationship, and patient-level detail, all in one pass.

The de-identification stage therefore strips and tokenizes every identity-bearing field before the records reach the open synthesis model. KOL names become stable pseudonymous tokens that preserve the ability to count distinct individuals without revealing who they are, so that the downstream clustering can still establish that nine separate physicians raised a concern without ever learning their names. Institutions are generalized to a tier or region rather than named. Patient anecdotes are reduced to the clinically relevant abstraction with the re-identifying specifics removed. The output of this stage is a de-identified corpus plus a securely held re-identification key that never enters the synthesis model's context, and the key is what allows an authorized human, later and deliberately, to trace a strategic signal back to the specific MSLs and engagements that produced it for follow-up. The gate is structural: the synthesis model literally cannot see what it was never given, which is the only form of privacy protection that survives an audit, because it does not depend on the model behaving well.

Stage Three: Clustering and Signal Weighting

With a de-identified corpus in hand, the workflow clusters the insights into themes and weights each cluster by strength of signal. Clustering is where the large language model earns its place, because semantic grouping across two hundred records written by fourteen different people in fourteen different styles is exactly the pattern-finding task models do extraordinarily well and humans do slowly and inconsistently. The model groups the records that are saying the same thing in different words, names the emerging themes, and proposes a hierarchy from broad therapeutic-area concerns down to specific product-attribute observations. The output is a candidate theme map, and it is genuinely useful as a first pass that no analyst could produce in the same time.

The discipline that makes the clustering defensible rather than merely impressive is the weighting layer, and it is where human judgment re-enters. A cluster's strategic weight is not its size; a single concern from one uniquely authoritative KOL can outrank a vague theme echoed by many, and a concern raised by nine independent physicians across six institutions carries different evidentiary force than the same count concentrated at one site. The workflow surfaces, for each cluster, the count of distinct pseudonymous KOLs, the spread across institution tiers, the recency, and the on-label or off-label composition, and it presents these as decision inputs to the medical-strategy lead rather than as an automated ranking. The model proposes the structure; the human assigns the strategic weight, because weighting is a judgment about what matters to the program, and that judgment is owned by the named medical-affairs lead, not by a clustering algorithm that cannot know which KOL the company most needs to hear.

Stage Four: The Strategic Medical-Affairs Report

The fourth stage drafts the strategic insights report itself, the deliverable that goes to the brand team and the medical-strategy lead, and the design goal is that every strategic claim in it traces to a cluster, every cluster traces to a count of de-identified sources, and every source can be re-identified by an authorized human through the held key if a claim needs to be defended. The model drafts the narrative: it articulates each strategic theme, characterizes the strength and direction of the signal, notes where the field view diverges from the published evidence, and flags the implications for the program. This is high-value generation, and it produces in an afternoon a report that historically took a senior analyst a week of manual collation to assemble.

The verification burden at this stage is precise and non-trivial. Because the model is generating strategic prose from a clustered corpus, it can quietly overstate a signal, attributing to the field a level of consensus the underlying counts do not support, or it can drift an on-label observation into an off-label inference because the linguistic boundary between them is subtle and the corpus contains both. The named author reconciles every strategic claim against the cluster it rests on, checks that the asserted strength matches the distinct-KOL count, and confirms that no off-label content has been laundered into an on-label recommendation. The report also has to keep the firewall visible: a field insight is a description of what KOLs said, not a directive to change a promotional message, and the workflow's output is medical intelligence for strategy, with any downstream commercial use routed through its own separate, governed path.

Stage Five: MLR-Cleared Dissemination

The final stage moves the report from a drafted document to a disseminated one through the medical-legal-regulatory review cycle, typically in Veeva PromoMats or the MedComms equivalent, and the workflow has to feed that review rather than fight it. MLR reviewers ask a predictable set of questions: is every claim substantiated, is the on-label or off-label status correct for the audience, is any patient or KOL identity exposed, and is the document's intended use consistent with its content and distribution. A report produced by the workflow described here answers all four by construction, because the de-identification gate already removed identity, the on-label flag was carried from intake, the strategic claims are already traced to source clusters, and the intended use was fixed at the design stage as internal medical intelligence rather than promotional material.

The audit trail is what turns a clean MLR pass into a defensible record. For the full run, the workflow captures the model and version used at each stage, the system prompt identities, the temperature settings, the timestamps, the de-identification configuration and the location of the secured re-identification key, the human weighting decisions, the named author's reconciliation of strategic claims to clusters, and the MLR disposition. When a compliance reviewer later asks how the company knows a strategic claim reflects genuine field consensus, the answer is not a recollection; it is a record showing the de-identified corpus, the cluster, the distinct-KOL count, and the human who weighted and signed it. The model accelerated the synthesis. The named medical-affairs lead owns the strategy, the de-identification gate owns the privacy, and the MLR cycle owns the release.

Validating the Workflow as a System

Because this is a Level 3 design, the workflow is not just operated; it is validated, and the validation mindset borrowed from computer-system assurance applies cleanly even though no individual stage is a medical device. The intended-use statement is written first and pins what the workflow is for: converting de-identified multi-MSL field records into a strategic medical-intelligence report for internal medical-affairs decision-making, explicitly not for generating promotional content. The fitness-for-purpose assessment then asks whether each stage's AI assistance is appropriate to its risk, and it lands differently per stage: normalization is low risk because a human reviews the structured mapping, de-identification is high risk because a miss exposes identity, and clustering is moderate risk because errors are caught at the human weighting gate. That risk grading drives where verification effort concentrates, which is the operational meaning of the risk-based principle in the FDA-EMA Guiding Principles.

The performance qualification of the workflow is the part teams most often skip and inspectors most often probe. It means running the workflow on a representative sample of real field records with a known answer key, then measuring whether de-identification actually removed every identity, whether clustering grouped semantically equivalent insights without splitting or merging them wrongly, and whether the drafted report's asserted signal strengths matched the underlying counts. A de-identification stage that leaks one institution name in a hundred records is not qualified, and the only way to know is to test it against a deliberately seeded sample that includes the hard cases: a KOL referenced by role rather than name, a patient described obliquely, an institution implied by a study identifier. The qualification record, kept under change control, is what lets the medical-affairs function assert that the workflow performs as intended rather than merely that it ran, and it is the difference between a tool a team uses and a workflow a sponsor can defend.

Where the Workflow Breaks If You Cut a Corner

Each stage has a corner that teams under deadline pressure are tempted to cut, and each cut converts a defensible workflow into an indefensible one in a specific way. Skip normalization and paste raw notes straight into synthesis, and the topic taxonomy collapses, off-label conversations travel unflagged, and the clusters become unreliable because the model is grouping inconsistently structured inputs. Skip de-identification and run synthesis on identified records, and you have processed named investigators' private opinions and patient detail through an open model, which is the failure that ends careers and triggers privacy-breach notifications. Skip the human weighting and accept the model's automated ranking, and the report overstates a numerically large but strategically weak theme while burying the one authoritative KOL the program most needed to hear.

The deepest corner, and the one that looks safest to cut, is the re-identification key. A team that de-identifies but discards the linkage believes it has been maximally cautious, when in fact it has destroyed the workflow's defensibility, because a strategic claim that cannot be traced back to the engagements that produced it is a claim the company cannot substantiate when challenged. The correct design holds the key securely, outside the synthesis model's reach, available only to authorized humans for deliberate follow-up. Privacy and traceability are not in tension here; they are achieved by the same mechanism, the separation of the de-identified corpus the model sees from the key the model never sees. That separation is the entire architecture, and it is why de-identification in this workflow is a precondition rather than a feature.

Key Takeaways

• Field-insight synthesis is a five-stage workflow, not a summarization prompt. Intake and normalization, de-identification, clustering and weighting, strategic report drafting, and MLR-cleared dissemination each have a distinct failure mode that a one-shot summary cannot see, and the value of an insight lives in the cross-record pattern that only the full workflow can surface defensibly.
• De-identification is a non-negotiable precondition that gates every downstream step. The KOLs are named trial investigators, confidentiality-bound advisory members, and disclosed competing-interest authors, and the patients in their anecdotes can be re-identifiable, so the synthesis model must be given a de-identified corpus and never the identities, because privacy that depends on the model behaving well does not survive an audit.
• Clustering is the model's job; strategic weighting is the human's. Semantic grouping across heterogeneous notes is a pattern-finding task models do well, but a cluster's strategic weight is a judgment about what matters to the program, informed by distinct-KOL count and institutional spread rather than raw size, and that judgment is owned by the named medical-affairs lead.
• Every strategic claim must trace to a cluster, a source count, and a re-identification path. The model can overstate consensus or drift an on-label observation into an off-label inference, so the named author reconciles each claim to the cluster it rests on, confirms the asserted strength matches the count, and keeps the scientific-exchange firewall visible against any commercial use.
• Privacy and traceability are achieved by the same mechanism: separating the de-identified corpus from the securely held key. Discarding the re-identification key feels maximally cautious but destroys defensibility, because an unsubstantiable strategic claim cannot survive MLR or a compliance challenge; the audit trail records the de-identification configuration, the human weighting, the claim-to-cluster reconciliation, and the MLR disposition for the full run.